HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344.

被引：0
|
作者：
Hayes, D. F.
Thor, A.
Dressler, L.
Weaver, D.
Broadwater, G.
Goldstein, L.
Martino, S.
Ingle, J.
Henderson, I. C.
Berry, D.
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[3] Univ N Carolina, Chapel Hill, NC 27515 USA
[4] Univ Vermont, Burlington, VT 05405 USA
[5] Duke Univ, Durham, NC 27706 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] Inst Canc Res, Med Grp, Santa Monica, CA USA
[8] Mayo Clin, Rochester, MN USA
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
[10] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5S / 5S
页数：1
相关论文
共 50 条
  • [1] HER2 and response to paclitaxel in node-positive breast cancer
    Nash, Irwin
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (02): : 198 - 198
  • [2] HER2 and response to paclitaxel in node-positive breast cancer
    Hayes, Daniel F.
    Thor, Ann D.
    Dressler, Lynn G.
    Weaver, Donald
    Edgerton, Susan
    Cowan, David
    Broadwater, Gloria
    Goldstein, Lori J.
    Martino, Silvana
    Ingle, James N.
    Henderson, I. Craig
    Norton, Larry
    Winer, Eric P.
    Hudis, Clifford A.
    Ellis, Matthew J.
    Berry, Donald A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15): : 1496 - 1506
  • [3] DOES ADJUVANT CHEMOTHERAPY BENEFIT PATIENTS WITH NODE-POSITIVE, HORMONE-RECEPTOR POSITIVE, AND HER2 NEGATIVE BREAST CANCER?
    Harano, K.
    Hashimoto, K.
    Shimizu, C.
    Hirata, T.
    Yonemori, K.
    Tamura, K.
    Katsumata, N.
    Ando, M.
    Fujiwara, Y.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 90 - 91
  • [4] HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy
    Sudeep Gupta
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 252 - 253
  • [5] HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy
    Gupta, S.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (05): : 252 - 253
  • [6] Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and leukemia group B 9344
    Sartor, CL
    Peterson, BL
    Woolf, S
    FitzGerald, TJ
    Laurie, F
    Turrisi, AJ
    Bogart, J
    Henderson, IC
    Norton, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) : 30 - 40
  • [7] Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer
    Yang, Sherry X.
    Costantino, Joseph P.
    Kim, Chungyeul
    Mamounas, Eleftherios P.
    Nguyen, Dat
    Jeong, Jong-Hyeon
    Wolmark, Norman
    Kidwell, Kelley
    Paik, Soonmyung
    Swain, Sandra M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 2974 - 2981
  • [8] HER2 status and benefit from adjuvant trastuzumab in breast cancer
    Paik, Soonmyung
    Kim, Chungyeul
    Wolmark, Norman
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (13): : 1409 - 1411
  • [9] Adjuvant therapy in breast cancer HER2 positive
    Olivito, V.
    De Simone, R.
    La Gattuta, G.
    Lucia, M.
    Dima, G.
    Talarico, R.
    Filippelli, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII146
  • [10] Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    Tolaney, Sara M.
    Barry, William T.
    Dang, Chau T.
    Yardley, Denise A.
    Moy, Beverly
    Marcom, P. Kelly
    Albain, Kathy S.
    Rugo, Hope S.
    Ellis, Matthew
    Shapira, Iuliana
    Wolff, Antonio C.
    Carey, Lisa A.
    Overmoyer, Beth A.
    Partridge, Ann H.
    Guo, Hao
    Hudis, Clifford A.
    Krop, Ian E.
    Burstein, Harold J.
    Winer, Eric P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 134 - 141
12345